<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03634748</url>
  </required_header>
  <id_info>
    <org_study_id>TRUST CT</org_study_id>
    <nct_id>NCT03634748</nct_id>
  </id_info>
  <brief_title>Thrombolysis in stRoke With Unknown onSet Based on noncontrasT CT</brief_title>
  <acronym>TRUST CT</acronym>
  <official_title>Thrombolysis in stRoke With Unknown onSet Based on Non-contrasT CT (TRUST CT). An International, Multicenter, Registry-based Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St John of God Hospital, Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentric, observational, registry-based study of 0.9 mg/kg i.v. thrombolysis in wake-up
      stroke or stroke with unknown onset based on non-contrast CT appearance only
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thrombolysis in wake-up stroke (WUS) or stroke with unknown onset (SUO) has been recently
      proven to be safe and effective using magnetic resonance imaging (MRI). However, in most of
      the thrombolyzing hospitals worldwide MR imaging is not available. We hypothesize that
      pragmatic non-contrast CT (NCCT)-based WUS/SUO thrombolysis may be feasible and safe.

      Methods: TRUST-CT is an international multicenter registry-based study. WUS/SUO patients
      undergoing NCCT-based thrombolysis with NIHSS ≥ 4 and initial ASPECTS ≥ 7 are included and
      compared to propensity score matched non-thrombolyzed WUS/SUO controls. Primary endpoint is
      symptomatic intracranial hemorrhage (ICH); secondary endpoints include 24-hour NIHSS change
      of ≥ 4 and modified Rankin Score (mRS) at 90 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">December 31, 2018</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>sICH</measure>
    <time_frame>72hours</time_frame>
    <description>symptomatic ICH according to ECASS3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>mRS 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>mRS 90 days</description>
  </secondary_outcome>
  <enrollment type="Actual">117</enrollment>
  <condition>Stroke, Acute</condition>
  <eligibility>
    <study_pop>
      <textblock>
        wake-up stroke, unknown onset stroke
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion:

          1. Ischemic stroke with NIHSS ≥ 4

          2. Wake-up stroke or unknown onset stroke

          3. Age ≥ 18 years

          4. rtPA Bolus within 4.5h of awakening and/or within 4.5 of discovering symptoms

          5. rtPA Bolus within 30 min. of admission CT

        Exclusion:

          1. Noncontrast cranial CT scan with ASPECTS &lt; 7

          2. Evidence of intracranial or subarachnoid hemorrhage

          3. Inability to control systolic BP &gt;185mm Hg, or diastolic BP &gt;110mm Hg with IV
             antihypertensive medication

          4. Known coagulopathy or evidence of active bleeding

          5. Surgical procedures, subclavian arterial puncture, trauma, and gastrointestinal or
             genitourinary bleeding within 14 days of the event

          6. Patients taking oral anticoagulants and having an INR &gt;1.7

          7. A platelet count &lt;100 000, venous glucose either &lt;50 or &gt;450

          8. Premorbid mRS &gt; 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>St. Johns Hospital Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Bratislava</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Liptovsky Mikulas</name>
      <address>
        <city>Liptovský Mikuláš</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lausanne University Hospital</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Slovakia</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 14, 2018</study_first_submitted>
  <study_first_submitted_qc>August 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Dr. Sven Poli</investigator_full_name>
    <investigator_title>Deputy Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

